UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2

Structure (London), 2017-08, Vol.25 (8), p.1163-1174

2017

Volltextzugriff (PDF)

Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1

Journal of medicinal chemistry, 2017-07, Vol.60 (13), p.5857-5867

2017

Volltextzugriff (PDF)

Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1

Structure (London), 2015-12, Vol.23 (12), p.2341-2348

2015

Volltextzugriff (PDF)

Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)

Oncotarget, 2016-05, Vol.7 (21), p.30323-30335

2016

Volltextzugriff (PDF)

CA-170 - A Potent Small-Molecule PD-L1 Inhibitor or Not?

Molecules (Basel, Switzerland), 2019-08, Vol.24 (15), p.2804

2019

Volltextzugriff (PDF)

Development of the Inhibitors that Target the PD-1/PD-L1 Interaction-A Brief Look at Progress on Small Molecules, Peptides and Macrocycles

Molecules (Basel, Switzerland), 2019-05, Vol.24 (11), p.2071

2019

Volltextzugriff (PDF)

Programmed Death-1: Therapeutic Success after More than 100 Years of Cancer Immunotherapy

Angewandte Chemie (International ed.), 2014-02, Vol.53 (9), p.2286-2288

2014

Volltextzugriff (PDF)

Lifeact: a versatile marker to visualize F-actin

Nature methods, 2008-07, Vol.5 (7), p.605-607

2008

Volltextzugriff (PDF)

Design, Synthesis, Evaluation, and Structural Studies of C2-Symmetric Small Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein-Protein Interaction

Journal of medicinal chemistry, 2019-08, Vol.62 (15), p.7250-7263

2019

Volltextzugriff (PDF)

Bioactive Macrocyclic Inhibitors of the PD‐1/PD‐L1 Immune Checkpoint

Angewandte Chemie International Edition, 2017-10, Vol.56 (44), p.13732-13735

International ed. in English, 2017

Volltextzugriff (PDF)

Structure-Based Design of Mdm2/Mdmx-p53 Inhibitors Gets Serious

Angewandte Chemie (International ed.), 2011-03, Vol.50 (12), p.2680-2688

International ed. in English, 2011

Volltextzugriff (PDF)

A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018)

Expert opinion on therapeutic patents, 2018-09, Vol.28 (9), p.665-678

2018

Volltextzugriff (PDF)

A therapeutic patent overview of MDM2/X-targeted therapies (2014-2018)

Expert opinion on therapeutic patents, 2019-03, Vol.29 (3), p.151-170

2019

Volltextzugriff (PDF)

Correction: Reyes Romero et al. Computer- and NMR-Aided Design of Small-Molecule Inhibitors of the Hub1 Protein. Molecules 2022, 27 , 8282

Molecules (Basel, Switzerland), 2024-06, Vol.29 (12), p.2926

2024

Volltextzugriff (PDF)

Robust Generation of Lead Compounds for Protein-Protein Interactions by Computational and MCR Chemistry: p53/Hdm2 Antagonists

Angewandte Chemie (International ed.), 2010-07, Vol.49 (31), p.5352-5356

2010

Volltextzugriff (PDF)

Structural Characterization of a Macrocyclic Peptide Modulator of the PD-1/PD-L1 Immune Checkpoint Axis

Molecules (Basel, Switzerland), 2021-08, Vol.26 (16), p.4848

2021

Volltextzugriff (PDF)

Multicomponent Peptide Stapling as a Diversity‐Driven Tool for the Development of Inhibitors of Protein–Protein Interactions

Angewandte Chemie International Edition, 2020-03, Vol.59 (13), p.5235-5241

International ed. in English, 2020

Volltextzugriff (PDF)

Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery

Cell cycle (Georgetown, Tex.), 2010-03, Vol.9 (6), p.1104-1111

2010

Volltextzugriff (PDF)

Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells

Cancers, 2018-10, Vol.10 (11), p.396

2018

Volltextzugriff (PDF)

PD-L1 Inhibitors: Different Classes, Activities, and Mechanisms of Action

International journal of molecular sciences, 2021-10, Vol.22 (21), p.11797

2021

Volltextzugriff (PDF)

Transient Protein States in Designing Inhibitors of the MDM2-p53 Interaction

Structure (London), 2013-12, Vol.21 (12), p.2143-2151

2013

Volltextzugriff (PDF)

Design, Synthesis, and Biological Evaluation of 2‑Hydroxy-4-phenylthiophene-3-carbonitrile as PD-L1 Antagonist and Its Comparison to Available Small Molecular PD-L1 Inhibitors

Journal of medicinal chemistry, 2023-07, Vol.66 (14), p.9577-9591

2023

Volltextzugriff (PDF)

IGF2 Peptide-Based LYTACs for Targeted Degradation of Extracellular and Transmembrane Proteins

Molecules (Basel, Switzerland), 2023-11, Vol.28 (22), p.7519

2023

Volltextzugriff (PDF)

Computer- and NMR-Aided Design of Small-Molecule Inhibitors of the Hub1 Protein

Molecules (Basel, Switzerland), 2022-11, Vol.27 (23), p.8282

2022

Volltextzugriff (PDF)

Enabling large-scale design, synthesis and validation of small molecule protein-protein antagonists

PloS one, 2012-03, Vol.7 (3), p.e32839

2012

Volltextzugriff (PDF)

1 – 25 von 233

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(224)
Mit Volltextzugriff
(224)

Publikationsform

Artikel
(231)
Buchkapitel
(2)

Sprache

Englisch
(229)
Deutsch
(5)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2

Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1

Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1

Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)

CA-170 - A Potent Small-Molecule PD-L1 Inhibitor or Not?

Development of the Inhibitors that Target the PD-1/PD-L1 Interaction-A Brief Look at Progress on Small Molecules, Peptides and Macrocycles

Programmed Death-1: Therapeutic Success after More than 100 Years of Cancer Immunotherapy

Lifeact: a versatile marker to visualize F-actin

Design, Synthesis, Evaluation, and Structural Studies of C2-Symmetric Small Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein-Protein Interaction

Bioactive Macrocyclic Inhibitors of the PD‐1/PD‐L1 Immune Checkpoint

Structure-Based Design of Mdm2/Mdmx-p53 Inhibitors Gets Serious

A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018)

A therapeutic patent overview of MDM2/X-targeted therapies (2014-2018)

Correction: Reyes Romero et al. Computer- and NMR-Aided Design of Small-Molecule Inhibitors of the Hub1 Protein. Molecules 2022, 27 , 8282

Robust Generation of Lead Compounds for Protein-Protein Interactions by Computational and MCR Chemistry: p53/Hdm2 Antagonists

Structural Characterization of a Macrocyclic Peptide Modulator of the PD-1/PD-L1 Immune Checkpoint Axis

Multicomponent Peptide Stapling as a Diversity‐Driven Tool for the Development of Inhibitors of Protein–Protein Interactions

Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery

Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells

PD-L1 Inhibitors: Different Classes, Activities, and Mechanisms of Action

Transient Protein States in Designing Inhibitors of the MDM2-p53 Interaction

Design, Synthesis, and Biological Evaluation of 2‑Hydroxy-4-phenylthiophene-3-carbonitrile as PD-L1 Antagonist and Its Comparison to Available Small Molecular PD-L1 Inhibitors

IGF2 Peptide-Based LYTACs for Targeted Degradation of Extracellular and Transmembrane Proteins

Computer- and NMR-Aided Design of Small-Molecule Inhibitors of the Hub1 Protein

Enabling large-scale design, synthesis and validation of small molecule protein-protein antagonists

Suchergebnisse filtern